Illinois Municipal Retirement Fund grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 31.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,652 shares of the company’s stock after purchasing an additional 2,061 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Medpace were worth $5,400,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Johnson Financial Group Inc. acquired a new stake in shares of Medpace in the 2nd quarter worth about $27,000. Jones Financial Companies Lllp bought a new stake in Medpace in the 2nd quarter valued at about $30,000. Allied Private Wealth LLC bought a new position in Medpace in the 2nd quarter worth about $31,000. Kilter Group LLC bought a new position in Medpace in the 2nd quarter worth about $31,000. Finally, Basecamp Wealth Advisors LLC grew its position in Medpace by 187.5% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after purchasing an additional 45 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.
Medpace Stock Performance
NASDAQ MEDP opened at $653.94 on Monday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $693.97. The business’s fifty day moving average is $629.52 and its two-hundred day moving average is $533.79. The stock has a market capitalization of $18.29 billion, a P/E ratio of 36.25, a P/E/G ratio of 2.54 and a beta of 1.12.
Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, topping analysts’ consensus estimates of $4.44 by $0.40. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The firm had revenue of $716.00 million for the quarter, compared to analysts’ expectations of $714.47 million. During the same quarter last year, the business posted $3.86 EPS. Medpace’s revenue was up 8.5% on a year-over-year basis. On average, research analysts forecast that Medpace Holdings, Inc. will post 18.06 earnings per share for the current year.
Insider Activity
In related news, VP Susan Burwig sold 16,060 shares of the stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $677.00, for a total value of $10,872,620.00. Following the transaction, the vice president owned 57,624 shares in the company, valued at approximately $39,011,448. This represents a 21.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO August Troendle sold 49,018 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the transaction, the chief executive officer owned 433,372 shares in the company, valued at approximately $272,205,286.92. This trade represents a 10.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 306,539 shares of company stock worth $191,774,429. Insiders own 20.50% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on MEDP. UBS Group lifted their price target on Medpace from $673.00 to $700.00 and gave the company a “neutral” rating in a report on Friday, October 23rd. BMO Capital Markets increased their price objective on Medpace from $600.00 to $670.00 and gave the stock a “market perform” rating in a report on Monday, October 26th. Deutsche Bank restated a “hold” rating and issued a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Mizuho set a $730.00 target price on Medpace in a research note on Friday, October 23rd. Finally, Truist Financial lifted their target price on Medpace from $609.00 to $633.00 and gave the company a “hold” rating in a research note on Friday, October 23rd. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, Medpace has a consensus rating of “Hold” and an average target price of $649.27.
Get Our Latest Stock Report on MEDP
Medpace Profile
Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.
Further Reading
- Five stocks we like better than Medpace
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
